Despite the DUX4-mediated suppression of MHC class I, therapies aimed at enhancing antigen presentation or modulating the tumor microenvironment to promote immune cell infiltration could mitigate DUX4-induced immune suppression [52]. This evidence concerns the gene DUX4 and neoplasm.